Kim Harry K W, Feng Gen-Sheng, Chen Di, King Philip D, Kamiya Nobuhiro
Texas Scottish Rite Hospital for Children, Dallas, TX, USA; Orthopaedic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
J Bone Miner Res. 2014 Mar;29(3):761-9. doi: 10.1002/jbmr.2062.
Metachondromatosis is a benign bone disease predominantly observed in the hands and feet of children or young adults demonstrating two different manifestations: a cartilage-capped bony outgrowth on the surface of the bone called exostosis and ectopic cartilaginous nodules inside the bone called enchondroma. Recently, it has been reported that loss-of-function mutations of the SHP2 gene, which encodes the SHP2 protein tyrosine phosphatase, are associated with metachondromatosis. The purpose of this study was to investigate the role of SHP2 in postnatal cartilage development, which is largely unknown. We disrupted Shp2 during the postnatal stage of mouse development in a chondrocyte-specific manner using a tamoxifen-inducible system. We found tumor-like nodules on the hands and feet within a month after the initial induction. The SHP2-deficient mice demonstrated an exostosis-like and enchondroma-like phenotype in multiple bones of the hands, feet, and ribs as assessed by X-ray and micro-computed tomography (CT). Histological assessment revealed the disorganization of the growth plate cartilage, a cartilaginous protrusion from the epiphyseal bone, and ectopic cartilage nodules within the bones, which is consistent with the pathological features of metachondromatosis in humans (ie, both exostosis and enchondroma). At molecular levels, we observed an abundant expression of Indian hedgehog protein (IHH) and fibroblast growth factor 2 (FGF2) and impaired expression of mitogen-activated protein kinases (MAPK) in the affected cartilage nodules in the SHP2-deficient mice. In summary, we have generated a mouse model of metachondromatosis that includes manifestations of exostosis and enchondroma. This study provides a novel model for the investigation of the pathophysiology of the disease and advances the understanding of metachondromatosis. This model will be useful to identify molecular mechanisms for the disease cause and progression as well as to develop new therapeutic strategies in the future.
软骨瘤病是一种主要在儿童或年轻成人的手和足部观察到的良性骨病,表现为两种不同的形式:一种是在骨表面的软骨帽状骨赘,称为外生骨疣;另一种是骨内的异位软骨结节,称为内生软骨瘤。最近,有报道称,编码SHP2蛋白酪氨酸磷酸酶的SHP2基因突变与软骨瘤病有关。本研究的目的是探讨SHP2在出生后软骨发育中的作用,而这在很大程度上尚不清楚。我们使用他莫昔芬诱导系统,以软骨细胞特异性方式在小鼠发育的出生后阶段破坏Shp2。在初次诱导后一个月内,我们在小鼠的手和足部发现了肿瘤样结节。通过X射线和微型计算机断层扫描(CT)评估,SHP2缺陷小鼠在手部、足部和肋骨的多块骨骼中表现出类似外生骨疣和内生软骨瘤的表型。组织学评估显示生长板软骨紊乱、骨骺骨的软骨突出以及骨内的异位软骨结节,这与人类软骨瘤病的病理特征一致(即外生骨疣和内生软骨瘤)。在分子水平上,我们观察到SHP2缺陷小鼠受影响的软骨结节中印度刺猬蛋白(IHH)和成纤维细胞生长因子2(FGF2)表达丰富,而丝裂原活化蛋白激酶(MAPK)表达受损。总之,我们建立了一个包括外生骨疣和内生软骨瘤表现的软骨瘤病小鼠模型。本研究为该疾病的病理生理学研究提供了一个新模型,并增进了对软骨瘤病的理解。该模型将有助于识别疾病发生和进展的分子机制,并在未来开发新的治疗策略。